| Ytd | -67.36% | |
| 1y | -48.97% |
| Open | 4.78 | Prev Close | 4.84 | Low | 4.61 | High | 4.87 | Mkt Cap | 9.46M |
| Vol | 57.67K | Avg Vol | 244.15K | EPS | -10.07 | P/E | N/A | Forward P/E | -0.43 |
| Beta | 1.89 | Short Ratio | 0.20 | Inst. Own | 5.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 5.15 | 200-d Avg | 9.27 | 1yr Est | 4.50 |
QNRX News
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinica
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical
The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan's Ministry
Six pediatric NS patients are currently enrolled in the program, all under 10 years of age, with the
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical
The IND submission is supported by clinical observations from Quoin's ongoing investigator-led p